Earnings call transcript: Bioatla beats Q1 2025 earnings expectations
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed financial performance with reduced net loss and R&D expenses, but significant cash depletion and no shareholder return initiatives. Regulatory and competitive risks are high, and the Q&A section highlights management's evasive responses, particularly regarding critical data updates. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks, especially given the absence of a market cap for context.
Key Financial Performance
Research and Development Expenses $12,400,000 (decreased by $6,500,000 or 34.4% year-over-year) due to lower clinical development expenses for Phase two trials as certain trials are completed, partially offset by a $500,000 charge related to workforce reduction.
General and Administrative Expenses $5,300,000 (decreased by $300,000 or 5.4% year-over-year) primarily due to lower stock-based compensation and lower D&O insurance premiums, offset by a $100,000 charge related to workforce reduction.
Net Loss $15,300,000 (decreased by $7,900,000 or 34.0% year-over-year) compared to a net loss of $23,200,000 in the same quarter of 2024.
Net Cash Used in Operating Activities $16,300,000 (decreased by $14,500,000 or 47.0% year-over-year) compared to $30,800,000 for the same period in 2024.
Cash and Cash Equivalents $32,400,000 as of 03/31/2025 (decreased from $49,000,000 as of 12/31/2024) reflecting the cash used in operations.
Cash Used for the Quarter $16,700,000 for the quarter ended 03/31/2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Dual CAB EpCAM and CD3 T cell engager: The Phase one dose escalation study is progressing well, with multiple patients achieving tumor reduction and tolerating therapy over months without progression.
MACV ADC: Demonstrated exceptional overall survival at the 1.8 mg/kg Q2W dosing regimen, with a two-year landmark survival of 59% in MKRAS non-small cell lung cancer patients.
OSV ADC: Showed a 100% disease control rate and a 45% overall response rate in treatment-refractory HPV positive head and neck cancer patients.
CAB CTLA-4 antibody avastatug: Observed a 67% overall response rate and a 92% disease control rate in patients with metastatic cutaneous melanoma.
Partnership Discussions: Ongoing discussions with multiple potential collaborators to maximize the value of clinical assets.
R&D Expenses: R&D expenses decreased to $12.4 million for Q1 2025 from $18.9 million in Q1 2024 due to lower clinical development expenses.
Cash Position: Cash and cash equivalents as of 03/31/2025 were $32.4 million, down from $49 million as of 12/31/2024.
Workforce Reduction: Announced a workforce reduction in March 2025 to align resources with prioritized programs.
Focus on Internal Programs: Focusing on two internal programs while exploring partnerships for others.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces uncertainties regarding the potential regulatory approval path for its product candidates, which could impact its business plans and prospects.
Financial Risks: BioAtlas reported a net loss of $15.3 million for Q1 2025, indicating ongoing financial challenges. The company has cash and cash equivalents of $32.4 million, which raises concerns about its ability to fund operations and R&D expenses in the future.
Competitive Pressures: The company is navigating a competitive landscape, particularly in the oncology sector, where other therapies are being developed for similar indications, which could affect market positioning.
Supply Chain Challenges: There are potential supply chain challenges that could impact the availability of materials needed for clinical trials and product development.
Workforce Reduction: The company announced a workforce reduction to align with its focus on two internal programs, which may affect operational capacity and morale.
Clinical Trial Risks: The success of ongoing clinical trials is uncertain, and any delays or failures could significantly impact the company's future prospects.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Programs Update: BioAtlas is advancing its Conditionally Active Biologic (CAD) platform, focusing on therapeutic candidates targeting solid tumors with high unmet medical needs.
Partnership Discussions: Ongoing discussions with multiple potential collaborators for Phase two clinical programs, particularly for CAVRORA2 ADC and avastatug.
Focus on Internal Programs: BioAtlas is prioritizing two internal programs after workforce reduction, while remaining open to partnerships for other assets.
Regulatory Engagement: Utilizing Fast Track designation for discussions with the FDA regarding treatment refractory metastatic HPV positive squamous cell carcinoma.
R&D Expenses: Expected to decrease for the remainder of 2025 due to restructuring and completion of Phase two trials.
Cash Runway: Sufficient cash runway to fund operations and achieve key clinical readouts in the first half of 2026, excluding funds from potential new partnerships.
Net Loss: Net loss for Q1 2025 was $15.3 million, an improvement from $23.2 million in Q1 2024.
Cash and Cash Equivalents: As of 03/31/2025, cash and cash equivalents were $32.4 million, down from $49 million as of 12/31/2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: BioAtlas has not announced any share repurchase program during the call.
Dividends: BioAtlas has not declared any dividends during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Will the poster presentation for the ROAR-two program at ASCO contain an updated data cut?
A:Yes, we do have an updated data cut that includes additional safety data and long-term outcomes.
Q:For the FCAM update in July, will we have data from the three hundred microgram dose as well as the nine hundred microgram dose?
A:I don’t think we have insight at the nine hundred microgram level at this point.
Q:Can you provide some color regarding the types of tumor regressions that you’re seeing?
A:We have seen two individuals with colorectal adenocarcinoma having extended progression-free intervals, but we haven’t yet observed a formal Resist response.
Q:How should we think about the landmark survival curves and the readouts?
A:We’re seeing landmark survivals because we haven’t hit the median survival yet, and our data are performing well compared to competitors.
Q:What is the ideal deal kind of look like for you guys?
A:I think of it in terms of more than one partnership, maintaining substantial value in North America and generating substantial cash value.
Q:Which are the two internal programs you’ll be focusing on moving forward?
A:We selected two initially, the OR2 and CTLA-four programs for partnering.
Q:When will we get data from the three hundred microgram cohort?
A:We want to get some visibility to the data at the midyear readout.
Q:What’s the regimen you guys are using to control the CRS in the study?
A:We use a standard approach with step dosing and employ atosolizumab prophylaxis.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the nine hundred microgram dose data availability, stating they do not have insight at this point. Additionally, they did not commit to declaring the expansion cohort dose level at the midyear readout.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BioAtlas Dr
BioAtlas question
CRS
Congress
Founder BioAtlas
HC Wainwright
KRAS cell
OSV
Officer BioAtlas
Oozarift
ROAR
approach KRAS
care
charge workforce
cohort dose
cross
cut
decrease
docetaxel
dose microgram
escalate
kind discussion
level point
microgram dose
midyear
month patient
question Dr
readout escalation
runway readout
slide
step
steroid
survival indication
trial indication
week regimen
workforce reduction
BCAB Transcript
Earnings call transcript: Bioatla beats Q1 2025 earnings expectations
Unknown5-6
The earnings call reveals a mixed financial performance with reduced net loss and R&D expenses, but significant cash depletion and no shareholder return initiatives. Regulatory and competitive risks are high, and the Q&A section highlights management's evasive responses, particularly regarding critical data updates. These factors suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks, especially given the absence of a market cap for context.
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
Positive11-9
The earnings call summary indicates a positive outlook with reduced R&D expenses, a significant decrease in net loss, and a promising worldwide license agreement. The Q&A section provides additional confidence in strategic execution, with management addressing cash sufficiency and clinical trial plans. Despite some concerns about supply chain and clinical trial risks, the overall sentiment leans positive due to strategic partnerships and shareholder value focus, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
Unknown8-11
The earnings call reveals financial and clinical uncertainties. Despite a decreased net loss, cash reserves have significantly declined, raising sustainability concerns. Management's vague responses in the Q&A regarding FDA feedback and efficacy add to the uncertainty. Although there is confidence in potential partnerships, the financial risks and lack of clear guidance on critical trials overshadow positive sentiments. The market is likely to react negatively in the short term, anticipating further clarification and financial stability.
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
Unknown3-26
The earnings call summary reveals financial strain, with increased R&D expenses, decreased cash reserves, and a net loss. The Q&A section highlights uncertainties in clinical trial outcomes and management's reluctance to provide specific metrics for success. These factors indicate potential investor concerns, leading to a negative sentiment.
BCAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
